William Strohl, former vice president of biologics research at the BCoE, was promoted to head of Janssen's biotech-focused drug development group. His previous role was filled by Robert Friesen, who came from J&J's Crucell Vaccine Institute. Barry…
written on 17.06.2014
BioNotebook: Janssen hunts for biologics; Aduro, Celsion/EGEN, Agios/Celgene and Aeterna Zentaris
Latest Reports
Perspectives from J.P. Morgan’s 2019 Health Care Investor Conference
Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P.…
Company Profile: Samsung BioLogics
It was less than a decade ago (2011) that Samsung BioLogics was a new kid on the block amongst Korea’s booming…
Real-World Evidence – A Game Changer for Pharma
Nawal Roy is founder and CEO of Holmusk, a company dedicated to building one of the world’s largest real-world…